Deal Watch: Beyond Pfizer/AstraZeneca, Plenty Of Fish In The Sea
Executive Summary
Deals continue outside of the focus on Pfizer/AstraZeneca, with Novartis expanding its ophthalmology portfolio; Viking licensing five metabolic disease candidates from Ligand; BioAlliance and Topotarget moving closer to a merger creating a new orphan oncology firm to be called Onxeo; Ventrus and Assembly planning their own merger to focus on hepatitis B; and Daiichi Sankyo and Sanford-Burnham signing an R&D collaboration on novel cardiovascular and metabolic disease targets.